Navigating the New Normal: Living with the EU11 Variant

As the world grapples with the ongoing COVID-19 pandemic, a new player has entered the scene – the EU11 variant. Emerging as a distant descendant of the XBB15 variant, this strain has garnered attention as it accounts for 1.7% of cases nationwide in the United States. Although still in its infancy, health authorities are closely monitoring its spread and potential impact.

The Center for Disease Control and Prevention (CDC) has been diligently tracking the emergence of the EU11 variant, with a particular focus on its concentration in different states. As of the latest data, Utah leads with 97 reported cases, followed by California with 38 cases and New York with 12. These numbers, while currently manageable, raise questions about the variant’s future trajectory and whether it will become a dominant strain.

To shed light on the situation, an interview with Dr. William Schaffner, the medical director of the National Foundation for Infectious Diseases, explores the efficacy of existing vaccines against EU11. With the ongoing efforts to adapt vaccines to changing strains, manufacturers like Pfizer, Moderna, and Novavax are gearing up to modify their formulations.

In a recent FDA VRBPAC meeting, discussions centered on the composition of this year’s COVID-19 vaccines, considering the dominant variants in circulation. The consensus was to recommend monovalent vaccines with proteins targeting the XBB lineage, a decision aimed at enhancing vaccine efficacy against prevalent strains.

Moderna, being proactive in response to the emerging variant, became the first to apply for authorization of its updated vaccine for the upcoming seasonal respiratory virus season. The move is part of a broader strategy to stay ahead of potential challenges posed by evolving strains. Novavax, too, expressed readiness for the fall, aligning with the VRBPAC recommendation.

In a statement, John C. Jacobs, President and CEO of Novavax, emphasized the company’s commitment to offering an alternative vaccine choice. The anticipation of regulatory guidance from authorities like the FDA, the World Health Organization, and the European Medicines Agency has positioned Novavax to contribute to global vaccination efforts.

As we navigate the uncertainties of the ongoing pandemic, the emergence of the EU11 variant underscores the importance of adaptability in our approach. Vigilance, research, and collaborative efforts between health authorities and vaccine manufacturers will play a crucial role in determining how we address this new chapter in our fight against COVID-19. Stay informed, stay safe.

Scroll to Top